Comparison of 18 F-FDG PET/MRI, MRI, and 18 F-FDG PET/CT for the detection of synchronous cancers and distant metastases in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma

We examined 198 consecutive patients with biopsy-proven OHSCC who agreed to receive chemoradiation. All patients underwent pretreatment PET/MRI and PET/CT on the same day. Patients were followed-up for a minimum of 12  months or until death. The McNemar’s test and receiver-operating characteristic (ROC) curves were used to compare sensitivity/specificity and the diagnostic capabilities of PET/MRI, MRI, and PET/CT, respectively.ResultsWe identified 55 patients (27.7%) who had synchronous cancers and/or distant metastases (number of involved sites: 83). The results of site-based analysis revealed that the sensitivity of PET/MRI was 15.7% higher than that of MRI (73.5% versus 57.8%,p 
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research

Related Links:

Conditions:   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage IV HPV-Mediated (p16-Positive ) Oropharyngeal Carcinoma AJCC v8;   Recurrent Head and Neck Squamous Cell Carcinoma;   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Oral ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: The RP2D of Debio 1143 is 200 mg/day for 14 days, q3w when combined with concomitant high-dose cisplatin chemoradiotherapy in LA-SCCHN. Debio 1143 addition to chemoradiotherapy was safe and manageable. Preliminary efficacy is encouraging and supports further development. PMID: 32994295 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Conditions:   Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Locally Advanced Head and Neck Squamous Cell Carcinoma;   Locally Advanced Hypopharyngeal Squamous Cell Car cinoma;   Locally Advanced Laryngeal Squamous Cell Carcinoma;   Locally Advanced Oral Cavity Squamous Cell Carcinoma;   Locally Advanced Oropharyngeal Squamous Cell Carcinoma;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stag...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
POSITIVE EXPRESSION OF NEDD9 IN HEAD AND NECK CANCER IS RELATED TO BETTER SURVIVAL PERIOD. Acta Clin Croat. 2019 Dec;58(4):655-661 Authors: Ledinsky Opačić I, Gršić K, Šitić S, Penavić I, Pastorčić Grgić M, Šarčević B Abstract The aim was to determine immunohistochemical expression of NEDD9 protein in head and neck squamous cell carcinoma (HNSCC) and the possible relation of its expression with primary tumor size (T), regional lymph node status (N), stage of disease (TNM) and survival period. A total of 131 patients with primary tumor localization in the area of oropharyn...
Source: Acta Clinica Croatica - Category: General Medicine Tags: Acta Clin Croat Source Type: research
ConclusionsSurveillance by gastrointestinal endoscopy every 6  months and surveillance by an otolaryngologist every 12 months could detect second primary head and neck cancers at an early stage, thereby facilitating minimally invasive treatment.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma;   Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7;   Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7;   Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Hypopharyngeal Squ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Hypopharyngeal Cancer | Nuclear Medicine | Oropharyngeal Cancer | Skin Cancer | Squamous Cell Carcinoma | Study